Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- Govt Panel Approves Plan for Special Zone in Kansai Area Where Mixed-Healthcare Using Unapproved Drugs Will Be Permitted
September 26, 2014
- Editor’s Pick: Five Healthcare News Headlines for September 8 – September 19
September 25, 2014
- Copayment Hike for New Drugs Up for Discussion towards Healthcare Overhaul
September 25, 2014
- MHLW Approves Additional Indications for Aricept, 2 Other Drugs
September 22, 2014
- MHLW Guidelines to Call for Thorough Internal Communications at Pharmas after Novartis’ Delayed ADR Reporting
September 19, 2014
- MHLW Official Concerned about Generic Codevelopment, but Denies Plans to Press for Industry Consolidation
September 19, 2014
- Selexipag, 4 Other APIs Designated as Orphan Drugs
September 19, 2014
- MHLW Launches Discussions on Requirements for Legally Backed Clinical Research Core Hospitals
September 17, 2014
- Regulatory Reform Council to Monitor Progress on Proposed Pricing Overhaul of Innovative Drugs
September 17, 2014
- MHLW Orders Revision of Package Insert for Lyrica
September 17, 2014
- PMDA Issues Alert on Administration of ARBs and ACE Inhibitors in Pregnant Women
September 12, 2014
- US FDA Approves Obesity Treatment Contrave; Takeda Has Marketing Rights
September 12, 2014
- EAD Director to Visit 5 Public Hospital Groups to Encourage Quick Settlement of Price Negotiations
September 12, 2014
- Chuikyo at Odds over Disclosure of Cost-Effectiveness Case Study Data to Companies
September 11, 2014
- Chuikyo’s Drug Pricing Panel to Continue Discussions on Penalties and Actions against Novartis
September 11, 2014
- Drug Costs Made Up 21.9% of Japan Healthcare Spending in FY2011: MHLW
September 11, 2014
- MLHW to Issue Development Request for Vaccines that Require Fewer Doses
September 11, 2014
- New Minister Eager to Keep 30% Deduction Cap for R&D Tax Credit System
September 10, 2014
- Jichi Medical University President Seen as Prime Candidate for Japan NIH Head
September 10, 2014
- Takeda Chairman Removed from Competitiveness Panel
September 9, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…